Western biopharma companies are increasingly turning to China to source innovation, as pharma’s dreaded “patent cliff” draws closer. Western biopharma companies are increasingly turning to China to source innovation, as pharma’s dreaded “patent cliff” draws closer.
Your trusted source for real-time market insights, expert analysis, and breaking financial news. We deliver actionable updates on global markets, stocks, crypto, and economic trends empowering investors to make informed decisions every day.
Contact us: contact@financeworld-news.com
© Copyright 2025 - financeworld-news.com